- Home
- AAT vs SVRA Comparison
AAT vs SVRA Comparison
Compare AAT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAT | SVRA |
|---|---|---|
| Founded | 1967 | 2007 |
| Country | United States | United States |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2010 | 2009 |
Fundamental Metrics
Financial Performance| Metric | AAT | SVRA |
|---|---|---|
| Price | $24.31 | $5.49 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $19.50 | $7.33 |
| AVG Volume (30 Days) | 367.5K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $0.22 | $430.87 |
| P/E Ratio | $303.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.72 | $2.43 |
| 52 Week High | $25.97 | $7.01 |
Technical Indicators
Market Signals| Indicator | AAT | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 44.29 |
| Support Level | $23.69 | $5.32 |
| Resistance Level | $24.85 | $6.15 |
| Average True Range (ATR) | 0.49 | 0.30 |
| MACD | -0.21 | -0.07 |
| Stochastic Oscillator | 15.31 | 9.72 |
Price Performance
Historical ComparisonAbout AAT American Assets Trust Inc.
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).